IP Library › Granted Patent US 12,357,588
Granted Patent B2
US 12,357,588 · App. 17/875,679 · Granted Jul 15, 2025

Pharmaceutical composition for reducing local fat and uses thereof

Inventor: Yu-Fang Ling (New Taipei, TW)
Assignee: Caliway Biopharmaceuticals Co., Ltd.
A61K31/12A61K8/11A61K8/347A61K8/86A61K9/0019A61K9/08A61K9/107A61K9/1075A61K31/05A61K36/82A61K45/06A61K47/44A61P43/00A61Q19/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,357,588
App. No.
17/875,679
Granted
Jul 15, 2025
Kind
B2
Abstract

The present invention provides a pharmaceutical composition for reducing localized fat, comprising drug-containing micelles made of surfactants, and curcumin encapsulated in said drug-containing micelles. This pharmaceutical composition for reducing localized fat can reduce the fat at the administration site, and has the advantages of high stability, high bioavailability for fat tissue, few side effects, and sustained release.

Claims (25)

1. A method for reducing body weight of a subject, comprising administering a pharmaceutical composition to the subject,

wherein the pharmaceutical composition comprises:

a first plurality of drug-containing micelles; and

a curcuminoid, which is encapsulated in said first plurality of drug-containing micelles;

wherein the first plurality of drug-containing micelles has a microstructure formed by a first pharmaceutically acceptable non-ionic surfactant, which has a hydrophilic-lipophilic balance (HLB) value greater than 10; wherein the non-ionic surfactant comprises polysorbate 80, polyoxyl 15 hydroxystearate, a polyoxyethylene castor oil derivative, or a combination thereof; wherein the weight ratio of the curcuminoid to the first non-ionic surfactant in the first plurality of drug-containing micelles is 1:8 to 1:500.

2. The method of claim 1 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable aqueous solution.

3. The method of claim 1 , wherein the pharmaceutical composition further comprises a second plurality of lipophilic drug-containing micelles; wherein the second plurality of lipophilic drug-containing micelles has a second microstructure formed by a second non-ionic surfactant, and a lipophilic drug, which is encapsulated in said second plurality of lipophilic drug-containing micelles, and the lipophilic drug comprises quercetin, synephrine, puerarin, resveratrol, or a combination thereof.

4. The method of claim 1 , wherein the pharmaceutical composition further comprises a hydrophilic drug, which comprises green tea extract, epicatechin, epicatechin gallate, epigallocatechin, gallocatechin gallate, gallocatechin, catechin gallate, catechin, epigallocatechin gallate (EGCG), caffeine, carnitine, L-carnitine, synephrine, chlorogenic acid, or a combination thereof.

5. The method of claim 1 , wherein the pharmaceutical composition is administered to the subject by subcutaneous injection, intravenous injection, or subcutaneous fat layer injection.

6. The method of claim 5 , wherein the pharmaceutical composition is injected at a local site of the subject at a dose of 0.2˜16 mg/cm 2 .

7. The method of claim 5 , wherein the pharmaceutical composition is injected at a local site of the subject at a dose of 0.4˜40 mg/kg.

8. The method of claim 5 , wherein the pharmaceutical composition is administered at a local site of the subject at a frequency of 3˜60 times every other day to every 20 days.

9. The method of claim 1 , wherein the pharmaceutical composition further comprises a cosolvent, a suspending agent, an oil phase excipient, or a combination thereof.

10. The method of claim 9 , wherein the pharmaceutical composition further comprises the cosolvent and the oil phase excipient; and wherein the first plurality of drug-containing micelles is co-formed with the first non-ionic surfactant and at least one of the oil phase excipient and the cosolvent.

11. The method of claim 1 , wherein the pharmaceutical composition is a subcutaneous injection formulation, a subcutaneous fat layer injection formulation, an intravenous injection formulation, a solution for implanted infusion, a cream, or a patch.

12. The method of claim 1 , wherein the first non-ionic surfactant comprises one or more polyoxyethylene castor oil derivatives.

13. The method of claim 12 , wherein the polyoxyethylene castor oil derivative comprises polyoxyl 35 castor oil, polyoxyl 40 hydrogenated castor oil, or a combination thereof.

14. The method of claim 1 , wherein the curcuminoid is curcumin.

15. The method of claim 1 , wherein the diameter of the drug-containing micelles is 3-50 nm.

16. The method of claim 3 , wherein the second non-ionic surfactant has an HLB value greater than 10.

17. The method of claim 16 , wherein the second non-ionic surfactant comprises polysorbate 80, polyoxyl 15 hydroxystearate, polyoxyethylene castor oil derivatives, or a combination thereof.

18. The method of claim 17 , wherein the second non-ionic surfactant comprises polyoxyl 35 castor oil, polyoxyl 40 hydrogenated castor oil, or a combination thereof.

19. The method of claim 1 , wherein the concentration of the curcuminoid in the pharmaceutical composition is 0.3˜120 mg/g.

20. The method of claim 3 , wherein the weight ratio of the curcuminoid to the lipophilic drug is 30:1˜1:10.

21. The method of claim 4 , wherein the weight ratio of the curcuminoid to the hydrophilic drug is 30:1 to 1:10.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 1, 2022
From: LING, YU-FANG
To: CALIWAY BIOPHARMACEUTICALS CO., LTD.
Reel/Frame 060681/0951 →
Continuity (6)
Division 16749266 · Jan 22, 2020
Division 15754429
Continuation PCTCN2015088340 · Aug 28, 2015
Provisional Application 62299702 · Feb 25, 2016
Provisional Application 62257846 · Nov 20, 2015
Related Publication 20220362173A1 · Nov 17, 2022
References Cited (102)
US 6383482B1 · Gorsek · 2002 [cited by applicant]
US 6475530B1 · Kuhrts · 2002 [cited by applicant]
US 7923026B2 · Moschwitzer · 2011 [cited by applicant]
US 7977319B1 · Levine · 2011 [cited by applicant]
US 9458086B1 · Patel et al. · 2016 [cited by applicant]
US 10610496B2 · Ling · 2020 [cited by applicant]
US 20010021703A1 · Kosak · 2001 [cited by applicant]
US 20030147979A1 · Mae et al. · 2003 [cited by applicant]
US 20040071799A1 · Xu et al. · 2004 [cited by applicant]
US 20040146539A1 · Gupta · 2004 [cited by applicant]
US 20050267221A1 · Wellen · 2005 [cited by applicant]
US 20060121158A1 · Ferruzzi et al. · 2006 [cited by applicant]
US 20060188590A1 · Ono · 2006 [cited by applicant]
US 20090047371A1 · Turini et al. · 2009 [cited by applicant]
US 20090324703A1 · Frautschy et al. · 2009 [cited by applicant]
US 20100048887A1 · Anderson et al. · 2010 [cited by applicant]
US 20100129304A1 · Ahlnas · 2010 [cited by applicant]
US 20100316679A1 · Sinclair et al. · 2010 [cited by applicant]
US 20110009496A1 · Lunsmann et al. · 2011 [cited by applicant]
US 20110151103A1 · Gore · 2011 [cited by applicant]
US 20110281957A1 · Kuhrts · 2011 [cited by applicant]
US 20120088829A1 · Berl · 2012 [cited by applicant]
US 20120177623A1 · Naghavi et al. · 2012 [cited by applicant]
US 20130096143A1 · Falla et al. · 2013 [cited by applicant]
US 20130202572A1 · Hastings · 2013 [cited by applicant]
US 20130245118A1 · Kuhrts · 2013 [cited by applicant]
US 20130273175A1 · Finley · 2013 [cited by applicant]
US 20140141082A1 · Song · 2014 [cited by applicant]
US 20140348926A1 · Hoffman et al. · 2014 [cited by applicant]
US 20140348961A1 · Shimada et al. · 2014 [cited by applicant]
US 20150306165A1 · Ling et al. · 2015 [cited by applicant]
US 20160250129A1 · Kim et al. · 2016 [cited by applicant]
US 20160287533A1 · Banerjee et al. · 2016 [cited by applicant]
US 20170157195A1 · Ling et al. · 2017 [cited by applicant]
US 20180243211A1 · Ling · 2018 [cited by applicant]
US 20200163906A1 · Ling et al. · 2020 [cited by applicant]
US 20200197324A1 · Ling et al. · 2020 [cited by applicant]
US 20200338152A1 · Ling · 2020 [cited by applicant]
CN 1812764A · 2006 [cited by applicant]
CN 101095665A · 2008 [cited by applicant]
CN 101310718A · 2008 [cited by applicant]
CN 101632655A · 2010 [cited by applicant]
CN 102106816A · 2011 [cited by applicant]
CN 102357226A · 2012 [cited by applicant]
CN 103285401A · 2013 [cited by applicant]
CN 103989659A · 2014 [cited by applicant]
EP 1077211A2 · 2001 [cited by applicant]
EP 1582204A2 · 2005 [cited by applicant]
EP 3187189A1 · 2017 [cited by applicant]
JP 2007063137A · 2007 [cited by applicant]
JP 2007131603A · 2007 [cited by applicant]
JP 2008133272A · 2008 [cited by applicant]
JP 2011132151A · 2011 [cited by applicant]
TW 200427416A · 2004 [cited by applicant]
TW 201201794A · 2012 [cited by applicant]
TW 201540294A · 2015 [cited by applicant]
TW 201707685A · 2017 [cited by applicant]
WO WO2006087759A2 · 2006 [cited by applicant]
WO WO2007041276A2 · 2007 [cited by applicant]
WO 2007113008A2 · 2007 [cited by applicant]
WO WO2007112996A2 · 2007 [cited by applicant]
WO WO2009066303A2 · 2009 [cited by applicant]
WO WO2009158248A2 · 2009 [cited by applicant]
WO WO2010048114A1 · 2010 [cited by applicant]
WO WO2010062824A2 · 2010 [cited by applicant]
WO WO2010106191A1 · 2010 [cited by applicant]
WO 2014028607A1 · 2014 [cited by applicant]
WO WO2014138426A2 · 2014 [cited by applicant]
WO WO2015081319A2 · 2015 [cited by applicant]
WO WO2016029870A1 · 2016 [cited by applicant]
WO WO2017037593A2 · 2017 [cited by applicant]
[No Author Listed], Fat Burning Needle. Lofter.com. May 23, 2017. Accessible at lofter.com/tag/%E7%87%83%E8%84%82%E9%. 7 pages. [cited by applicant]
[No Author Listed], Kolliphor ELP | Macrogolglycerol ricinoleate Ph. Eur., Polyoxy1-35-castor oil USP/NF. BASF The Chemical Company. Mar. 2012. 4 pages. [cited by applicant]
[No Author Listed], Kolliphor RH 40 | Macrogolglycerolhydroxystearat Ph. Eur., Polyoxyl-40 Hydrogenated castor oil USP/NF. BASF The Chemical Company. Dec. 2011. 6 pages. [cited by applicant]
[No Author Listed], Lipolysis needle how to dissolved fat pin to lose weight myth. 39 Health Network. Jan. 1, 2015. Accessible at read01.com/kDAMky.html. 9 pages. [cited by applicant]
[No Author Listed], Quercetin—Increases Fat Metabolism and Fat Burning | Muscular Development. Written by Team MD. Jan. 14, 2014. Accessible at musculardevelopment.com/articles/fat-loss/12555-dietar. 2 pages. [cited by applicant]
[No Author Listed], Synephrine—Fat Burner Ingredient Profile. May 23, 2017. Accessible at youbutslimmer.com/synephrine-weight-loss-uk. 5 pages. [cited by applicant]
Cadena et al., Nanoencapsulation of quercetin and resveratrol into elastic liposomes. Biochim Biophys Acta. Feb. 2013;1828(2):309-16. doi: 10.1016/j.bbamem.2012.10.022. Epub Oct. 25, 2012. [cited by applicant]
Chen et al., Targeted delivery of curcumin to tumors via PEG-derivatized FTS-based micellar system. AAPS J. May 2014;16(3):600-8. doi: 10.1208/s12248-014-9595-6. Epub Apr. 5, 2014. [cited by applicant]
Cherniack, Polyphenols: planting the seeds of treatment for the metabolic syndrome. Nutrition. Jun. 2011;27(6):617-23. doi: 10.1016/j.nut.2010.10.013. Epub Mar. 2, 2011. Abstract Only. [cited by applicant]
Davis et al., The dietary flavonoid quercetin increases VO(2max) and endurance capacity. Int J Sport Nutr Exerc Metab. Feb. 2010;20(1):56-62. doi: 10.1123/ijsnem.20.1.56. [cited by applicant]
Dong et al., Effects of Curcuma Longa MeOH Extract on Adipogenesis and Lipolysis in 3T3-L1 Adipocycles. J Korean Soc Food Sci Nutr. 2009;11:347. [cited by applicant]
Hong et al., Several varieties of injections state with surfactantss quality specification and safety. Chinese J Experimental Traditional Medical Formulae. Jan. 2010;16(1):115-9. [cited by applicant]
Hu et al., Enhancement of Oral Bioavailability of Curcumin by a Novel Solid Dispersion System. AAPS PharmSciTech. Dec. 2015;16(6):1327-34. doi: 10.1208/s12249-014-0254-0. Epub Mar. 25, 2015. [cited by applicant]
Inchai et al., Investigation on Solubility and Stability of Curcumin in Aqueous Polysorbate Micelle. Int J Adv Sci Eng and Technol. IJASEAT. Oct. 2015;3(4):157-61. [cited by applicant]
Jannin et al., Formulation of a self-emulsifying lipid formulation of curcumin. AAPS Annual Meeting and Exposition. Nov. 2014. Poster R6159. doi: 10.13140/RG.2.2.31621.24809. 1 page. [cited by applicant]
Kang et al., Curcumin decreases oleic acid-induced lipid accumulation via AMPK phosphorylation in hepatocarcinoma cells. Eur Rev Med Pharmacol Sci. Oct. 2013;17(19):2578-86. [cited by applicant]
Kim et al., The current status of bladder preservation in the treatment of muscle invasive bladder cancer. J Urol. Sep. 2000;164(3 Pt 1):627-32. doi: 10.1097/00005392-200009010-00002. [cited by applicant]
Kiss et al., Kinetic analysis of the toxicity of pharmaceutical excipients Cremophor EL and RH40 on endothelial and epithelial cells. J Pharm Sci. Apr. 2013;102(4):1173-81. doi: 10.1002/jps.23458. Epub Jan. 29, 2013. [cited by applicant]
Meydani et al., Dietary polyphenols and obesity. Nutrients. Jul. 2010;2(7):737-51. doi: 10.3390/nu2070737. Epub Jul. 8, 2010. [cited by applicant]
Meydani, Curcumin modulation of angiogenesis and obesity. J Clin Biochem. Sep. 2011;44(13):S238-9. doi: 10.1016/j.clinbiochem.2011.08.583. [cited by applicant]
Naksuriya et al., Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials. Mar. 2014;35(10):3365-83. doi: 10.1016/j.biomateria… [cited by applicant]
Perez-Torres et al., Hibiscus sabdariffa Linnaeus (Malvaceae), curcumin and resveratrol as alternative medicinal agents against metabolic syndrome. Cardiovasc Hematol Agents Med Chem. Mar. 2013;11(1):25-37. doi: 10.2174… [cited by applicant]
Rachmawati et al., Size-Dependent of Oil Droplet of Curcumin Nanoemulsion on the In Vivo Release Kinetic of Curcumin After Oral and Intravenous Administrations in Animal Model. Adv Sci Eng Med. Sep. 2014;6(9):959-64. [cited by applicant]
Rayalam et al., Resveratrol induces apoptosis and inhibits adipogenesis in 3T3-L1 adipocytes. Phytother Res. Oct. 2008;22(10):1367-71. doi: 10.1002/ptr.2503. [cited by applicant]
Shafaghi et al., Prevalence of overweight and obesity among secondary school children (12-14 yr) in the city of Mashhad, Iran, 2010-11. Clin Biochem. Sep. 2011;44(13):S238-9. doi: 10.1016/j.clinbiochem.2011.08.581. [cited by applicant]
Yan et al., The study of weight control and the mechanism on the model of simplicity obesity rats by curcumin. J Xi'an Jiaotong Univ (Medical Sciences). Aug. 2006;27(4):387-90. [cited by applicant]
Zheng et al., Effects of puerarin on lipid accumulation and metabolism in high-fat diet-fed mice. PLoS One. Mar. 30, 2015;10(3):e0122925(1-11). doi: 10.1371/journal.pone.0122925. [cited by applicant]
U.S. Appl. No. 15/754,363, filed Feb. 22, 2018, Yu-Fang Ling. [cited by applicant]
U.S. Appl. No. 15/754,363, filed Feb. 22, 2018, Ling et al. [cited by applicant]
U.S. Appl. No. 16/926,631, filed Jul. 10, 2020, Ling et al. [cited by applicant]
(2015) “Surfactant Micelle Characterization using Dynamic Light Scattering”, Instrumat, Retrieved from internet: https://instrumat.ch/wp-content/uploads/ 2016/08/Surfactant-Micelle-Characterization-AN 101104-LRLL.pdf, R… [cited by applicant]